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resumo 
 
 
A lichenicidina é um lantipéptido da classe II constituído por dois péptidos, 
Bliα e Bliβ, produzido por diversas estirpes de Bacillus licheniformis. Estes 
péptidos atuam sinergisticamente, de forma a inibirem o crescimento de outras 
bactérias de Gram positivo, sendo por isso também designados de 
lantibióticos. Ao contrário de outros compostos antimicrobianos produzidos por 
bactérias, os lantibióticos são produzidos na sua forma imatura diretamente 
pelo ribossoma e sofrem diversas alterações pós-traducionais, que os tornam 
péptidos ativos. Desta forma, torna-se mais fácil a aplicação de técnicas de 
bioengenharia de modo a obter novas variantes com bioatividade alterada. 
Os objetivos deste trabalho foram i) a construção de um sistema de 
expressão heteróloga da lichenicidina em E. coli que permitisse a seleção 
azul/branco, ii) a construção de uma biblioteca por mutagénese aleatória para 
cada um dos péptidos que constituem a lichenicidina e iii) a seleção e análise 
de clones com bioatividade reduzida relativamente ao controlo. 
Para a criação do sistema de expressão heteróloga, foram realizados 
vários ensaios preliminares, que levaram à seleção da estirpe E. coli Mach1 
como recetora assim como à seleção da temperatura de produção de 37 ºC. 
Assim sendo, foram construídas duas bibliotecas por mutagénese aleatória 
dos genes estruturais licA1 e licA2, que codificam os péptidos percursores de 
Bliα e Bliβ, respetivamente. Subsequentemente, a bioatividade de cerca de 
4000 clones de cada biblioteca foi analisada através de bioensaio em agar. 
Através desta análise, não foi possível detetar nenhum clone com bioatividade 
aumentada em ambas as bibliotecas. Relativamente à biblioteca do péptido 
Bliα, cerca de 4,5 % dos clones apresentaram bioatividade nula, enquanto que 
2,6 % e 2,2 % dos clones apresentaram atividade muito reduzida e atividade 
reduzida a metade quando comparada com o controlo, respetivamente. Na 
biblioteca do péptido Bliβ, os valores foram bastante semelhantes, com cerca 
de 5,1 % dos clones a exibir atividade nula, 1,4 % com atividade muito 
reduzida e 3,8 % com atividade reduzida a metade quando comparada com o 
controlo. A sequência dos genes estruturais de alguns destes clones foram 
analisados, com o objetivo de identificar as alterações responsáveis por estes 
fenótipos. Esta análise confirmou a importância dos resíduos conservados 
para a bioatividade dos dois péptidos. Foi também possível reconhecer que 
substituições envolvendo aminoácidos carregados e prolinas resultam na 
produção de péptidos inativos.  
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abstract 
 
 
 
 
 
 
 
 
 
 
Lichenicidin is a class II lanthipeptide composed by two peptides, Bliα and 
Bliβ, that is produced by several strains of Bacillus licheniformis. These 
peptides act synergistically in order to inhibit the growth of other Gram positive 
bacteria. Due to their antibacterial activity, they are also designated lantibiotics. 
Unlike other antimicrobial peptides produced by bacteria, lantibiotics are 
ribosomally synthesized as an immature peptide and suffer several post-
translational modifications to achieve their active form. Thus, it is easier the 
application of bioengineering strategies aiming the creation of new variants with 
different bioactivity. 
The aims of this study were: i) the development a heterologous 
expression system for the production of lichenicidin allowing a white/blue 
selection and using E. coli, ii) the generation of two random mutagenesis 
libraries for each one of the lichenicidin peptides and iii) the selection and 
analysis of clones with reduced bioactivity when compared with the control. 
To develop the heterologous system, preliminary tests were conducted 
that allowed the selection of E. coli Mach1 as the recipient strain. In addition, 
37 ºC was established as the best temperature for lichenicidin production. 
Thus, two random mutagenesis libraries of the structural genes licA1 and licA2, 
encoding the precursor peptides of Bliα and Bliβ, respectively. Subsequently, 
the bioactivity of around 4000 clones of each library was analyzed by colony-
agar bioassay. In the present study, colonies with improved activity were not 
possible to detect in any of the libraries. Regarding the Bliα library, about 4,5 % 
of the clones showed null bioactivity, while 2,6 % and 2,2 % of the clones 
showed very reduced and activity reduced to half when compared with the 
control, respectively. In the Bliβ library, the values were very similar since about 
5,1 % of the clones showed no bioactivity, 1,4 % showed very reduced activity 
and 3,8 % had activity reduced to half when compared with the control. Some 
of these clones were selected for sequencing reaction in order to identify the 
mutations causing the observed phenotypes. This analysis confirmed the 
importance of the conserved residues for the bioactivity of both peptides. 
Moreover, it was found that substitutions involving charged amino acids and 
prolines result in the production of inactive peptides. 
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1. Introduction 
 
In the microorganisms, there are innumerous sets of microbial defense systems, such 
as antibiotics, lytic agents and exotoxins. Among the antimicrobial compounds produced 
by microorganisms are the peptides. These peptides are synthesized by two different 
mechanisms: ribosomal synthesis and nonribosomal synthesis. Nonribosomally 
synthesized peptides use large multienzyme complexes designated nonribosomal peptide 
synthetases (NRPSs), which produce the final peptides. Within this group are the peptides 
usually referred as the classic antibiotics. Peptides with antimicrobial activity produced by 
ribosomal synthesis are normally called bacteriocins (Cotter et al., 2005a; Nes et al., 
2007a; Arnison et al., 2013). 
1.1 Bacteriocins 
 
Bacteriocins can be defined as small and heat-stable bacterially produced 
antimicrobial peptides that are active against other bacteria. They can have a narrow 
spectrum (to the same species) or a broad spectrum of activity (across a genera) (Cotter 
et al., 2005a; Nes et al. 2007a). These toxins have been found in a widespread distribution 
in Bacteria and according to Klaenhammer (1988), 99 % of all bacteria should have the 
ability to synthesize at least one bacteriocin. Also, these compounds have been described 
in some lineages of the Archaea. Bacteriocins can be used as preservatives in food 
industry and as antibiotics in the pharmaceutical industry (Riley, 1998; Riley & Wertz, 
2002). 
These antimicrobial peptides can be produced by either Gram-positive or Gram-
negative bacteria. Bacteriocins produced by Gram-positive bacteria are generally small, 
consisting of 30-70 amino acids. Gram-positive bacteriocins are normally non-toxic to 
eukaryotic cells, and they have much broader inhibitory spectra compared to bacteriocins 
from the Gram-negative bacteria. Gram-negative bacteria generally produce relatively 
large and heat-labile bacteriocins (except microcins). Colicins produced by Escherichia coli 
are the most extensively studied, and it’s now known that its production is generally 
mediated by the SOS regulon and it is, therefore, mainly produced under stress 
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conditions, resulting on death of the producing cell and any neighboring cells (Riley & 
Wertz, 2002; Nes et al., 2007b).  
Due to its heterogeneity, the classification of bacteriocins is complex. According to 
the increasing knowledge of their biosynthesis, structure and mode of action, they have 
been grouped into four different classes with some subclasses. Different criteria have 
been used to classify them, such as the producer organisms, molecular sizes, physical 
properties, chemical structures and mode of action (Table 1) (Nes et al., 2007a; Rea et al., 
2011).  
Due to the limited scope of this thesis we will focus only on lanthipeptides with 
antimicrobial activity, which are included in Class I bacteriocins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Classifications scheme for bacteriocins. Adapted from Cotter et al. (2005a) and Rea et al. (2011). 
Classification Description Remarks 
Class I 
Lanthipeptides with 
antimicrobial activity- 
lantibiotics 
Small membrane-active 
peptides (<5 kDa). Contain 
the unusual amino acids 
lanthionine, β-methyl 
lanthionine and dehydrated 
residues. 
Nisin is the most 
characterized of 
the Class I 
bacteriocins. 
Class II 
Non-lanthionine-
containing bacteriocins 
Unmodified peptides. Small 
(<10 kDa) heat-stable 
membrane-active peptides. 
Divided into four 
subgroups: IIa, 
pediocin-like; IIb, 
two-peptide; IIc, 
cyclic; IId, non-
pediocin 
unmodified 
peptides. 
Class III 
Bacteriolysins 
Large (>30 kDa) heat-labile 
proteins. 
Large heat-labile 
proteins, often 
with enzymatic 
activity. 
Class IV 
Complex proteins 
Contain lipid or carbohydrate 
moieties. 
_ 
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1.2. Overview of Class I Bacteriocins – the Lanthipeptides 
 
The term lanthipeptide refers to the abbreviation of lanthionine-containing peptides. 
This term describes all the peptides that undergo the lanthionine- and melthyllanthionine 
modifications. Lanthipeptides with antimicrobial activity are called lantibiotics (Arnison et 
al., 2013). 
These peptides are small compounds (19-38 amino acids) that are ribosomally 
synthesized and suffer posttranslational modifications to achieve their biological active 
forms. All lanthipeptides possess the unusual amino acid lanthionine (Lan) in their 
structure that is formed by two alanine residues cross-linked via a thioether linkage 
connecting their β-carbons. In addition, lanthipeptides can also be characterized by the 
presence of 3-methyllanthionine (MeLan) amino acids. Both (Lan and MeLan) are the 
unifying structural motif present in all lanthipeptides (Chatterjee et al., 2005; Willey & 
van der Donk, 2007; Field et al., 2010; Arnison et al., 2013). Commonly, lanthipeptides 
contain the dehydrated amino acids 2,3-didehydroalanine (Dha) and (Z)-2,3-
didehydrobutyrine (Dhb), whereas further modified residues such as lysinoalanine, S-
aminOVinyl-D-CySteine, S-aminovinyl-D-methylcysteine and erythro-3-hydroxyaspartic 
acid are only found in individual peptides (Sahl et al., 2008; Arnison et al., 2013). 
The first isolated and arguably the most studied lantibiotic, nisin, is produced by 
Lactococcus lactis. This lantibiotic was discovered in 1928. However its structure was only 
revealed some years later (in 1971). Based on this discovery, it was proposed that the 
dehydrated amino acids in lantibiotics were the result of the dehydration of Thr and Ser 
residues, resulting in Dhb and Dha respectively. It was also suggested that Lan and MeLan 
rings were made by the reaction of Cys residues with these two dehydrated amino acids 
(Dha and Dhb) (Figure 1). However, this hypothesis was only confirmed after the 
elucidation of the nucleotide sequence of respective gene clusters (Chatterjee et al., 
2005; Willey & van der Donk, 2007; Bierbaum & Sahl, 2009). 
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Nowadays there are two classification schemes for lanthipeptides: i) the classification 
based on the their chemical structure and ii) the classification according to the enzymes 
that synthesize the Lan and MeLan residues (Chatterjee et al., 2005; Nes et al., 2007a; 
Bierbaum & Sahl, 2009). Considering the second classification scheme, the lanthipeptides 
are divided in four classes (Figure 2) (Knerr & van der Donk, 2012). In these classes, we 
can find differences in the leader peptide sequence, biosynthetic operon structure, 
peptide function, and the structure of the mature lantibiotic. Considering the biological 
activity, only lanthipeptides belonging to class I and class II show antimicrobial activity. 
The advantages of this classification scheme rely on its simplicity and flexibility to 
accommodate lanthionine-containing peptides that have not yet been discovered  (Willey 
& van der Donk, 2007).  
The lanthipeptides are biosynthesized by the ribosome as a precursor peptide 
generally designated by LanA. This precursor can be physically divided in a leader and a 
core peptide. The mature and active lanthipeptides are produced after the intervention of 
one or more enzymes that install the thioether cross-links in the core peptide, followed 
by removal of the leader peptide and export to the extracellular space.  
Figure 1: Mechanism of production of lanthionine (Lan) or methyllanthionine (MeLan) residues (Willey and Donk, 2007). 
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In class I lanthipeptides, LanA are modified by two distinct enzymes, LanB enzyme, 
which dehydrates Thr and Ser residues, and LanC, which mediates the cyclization step. 
Normally these lantibiotics are more linear than class II lanthipeptides. Class II 
lanthipeptides are modified by the LanM, which are large (900–1000 amino acids) 
proteins that exhibit both dehydratase and cyclase activities. The class III lanthipeptides 
are modified by a trifunctional synthetase bearing an N- terminal lyase domain, a central 
kinase domain, and a putative C-terminal cyclase domain, which lacks many of the 
conserved active-site residues found in LanC/LanM. In the more recently described class, 
class IV, the lanthipeptides are modified by LanL (continuing the common nomenclature 
for lantibiotic biosynthetic genes), that contains a N-terminal lyase and kinase domains as 
in class III, but its C-terminal cyclase domains is analogous to LanC (Figure 2) (Willey & van 
der Donk, 2007; Goto et al., 2010; Knerr & van der Donk, 2012).  
Lichenicidin is a class II lanthipeptide and is the object of the present work (Begley et 
al., 2009). 
 
 
 
1.2.1 Biosynthesis of Class II lanthipeptides  
 
The biosynthetic gene clusters of lanthipeptides are generally found in the host 
chromosome (e.g., lichenicidin) or in plasmids (e.g. lacticin 3147) (Chatterjee et al., 2005; 
Figure 2: Representation of conserved motifs of the four classes of lanthionine-generating enzymes. Abbreviations: 
LabKC, labionin synthetase; LanB, lantipeptide dehydratase; LanC, lantipeptide cyclase; LanL, class IV lantipeptide 
synthetase; LanM, class II lantipeptide synthetase; RamC, SapB-modifying synthetase (Knerr and van der Donk, 2012). 
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Willey & van der Donk, 2007). The genes for lanthipeptides biosynthesis have been 
designated with the generic locus symbol lan with a more specific designation for each 
lanthipeptide member (e.g., Lct for lacticin 481, Mrs for mersacidin). Many of these lan 
genes have been sequenced and a high degree of similarity is found on the gene 
organization of different lantibiotics (Chatterjee et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The gene clusters always comprise structural gene lanA, and also the genes encoding 
the modification enzymes and transporter/protease. The genes can differ in order, 
complexity and transcriptional organization. Generally, lanthipeptides with other unusual 
posttranslational modifications, also possess the genes encoding the enzymes required 
for that process in the same cluster (Chatterjee et al., 2005; Willey & van der Donk, 2007). 
Comparison of the gene sequences of different clusters allowed the identification of 
three genes that are involved in the biosynthesis of all class II lanthipeptides, which are 
lanA, lanM and lanT (Figure 4). The lanA is translated into the LanA precursor peptide, 
which is biologically inactive because it still contains the N-terminal leader peptide. The 
leader peptides of class II are rich in aspartate and glutamate residues and finish with a 
double-Gly motif (includes Gly-Gly, Gly-Ala and Gly-Ser sequences) (Chatterjee et al., 
2005). The C-terminal region of the precursor peptide is designated as core peptide. The 
Figure 3: General overview of biosynthesis of class II lanthipeptides (Caetano, 2011). 
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Ser and Thr residues can be present on both leader sequence and core peptide, whereas 
Cys residues are only found in the core peptide segment (Sahl & Bierbaum, 1998; Mcauli 
et al., 2001; Chatterjee et al., 2005). This is the region where the dehydration and 
cyclization post-translational modifications are introduced by the LanM enzyme. It 
corresponds to the mature and active lanthipeptide, after the removal of the leader 
peptide by the N-terminal protease domain of LanT. This proteolytic processing takes 
place at the double-Gly motif and can occur before or during export. The ABC transporter 
encoded by the C-terminal of LanT performs this export. The gene clusters can also 
contain a second transport system composed by lanE, lanF and lanG genes, which is 
related with the self-immunity of the producing strain. In some cases, a lanI gene is also 
present, which is believed to be involved also in self-protection (Figure 4). Finally, some 
clusters also possess genes encoding proteins involved in the regulation of lantibiotic 
production (LanK and LanR) comprising a two-component sensory system (Figure 4) 
(Chatterjee et al., 2005; Willey & van der Donk, 2007). The isolation of precursor peptides 
from the cytoplasm of producing strains has proved quite difficult, suggesting that these 
have a short half-life, being dehydrated immediately after synthesis (Mcauli et al., 2001). 
 
A growing subgroup within the class II lanthipeptides is the two-component peptides. 
In this subgroup, two peptides are needed to achieve the potent antimicrobial activity 
that results from their synergistic interaction. Each peptide is encoded by its own 
structural gene but are modified by separate LanM enzymes. Generally, a single LanT 
protein removes the leader peptide and secretes both products. Some of these 
compounds might undergo an additional N-terminal proteolytic step presumably by the 
Figure 4: Representation of biosynthetic gene clusters involved in the production of the most representative 
lanthipeptides from class II (Caetano, 2011). 
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action of an extracellular protease (Willey & van der Donk, 2007; Knerr & van der Donk, 
2012).  
 
1.2.1.1 Lichenicidin – Class II lantibiotic 
 
The lanthipeptides with antibacterial activity are designated as lantibiotics. Thus, 
lichenicidin is a two-component lantibiotic produced by several Bacillus licheniformis 
strains (Dischinger et al., 2009; Shenkarev et al., 2010; Caetano et al., 2011a). Although 
not recognized at the time, lichenicidin was firstly detected as a secondary metabolite of 
B. licheniformis I89, which was isolated from an hot spring environment (Mendo et al., 
2004). However, the first description of lichenicidin as a two-component lantibiotic was in 
2009, involving its production by B. licheniformis DSM13 (ATCC 14580). Later, it was also 
detected in B. licheniformis VK21 supernatants (Begley et al., 2009; Dischinger et al., 
2009; Shenkarev et al., 2010). 
The gene cluster of lichenicidin (Figure 5) is located at the far end of the 
chromosome, and is composed by 14 ORFs. It comprises the two structural genes (licA1 
for the mature α-peptide, Bliα and licA2 for mature β-peptide, Bliβ), the two bifunctional 
dehhydratases-cyclases modification enzymes (licM1 for modification of LicA1 and licM2 
for modification of LicA2), a processing transporter (LicT) that plays an essential role in 
removal of the leader peptide and the export of Bliα and Bliβ, and a peptidase (LicP) that 
was involved only in the Bliβ maturation. It was includes the licX gene which encodes a 
small uncharacterized hypothetical protein, but is known that LicX does not play an 
essential role in lichenicidin production. The role of LicR and LicY in the biosynthesis was 
not established yet. Finally, the gene cluster contains a group of 5 ORFs, putatively 
involved in lichenicidin immunity (Begley et al., 2009; Dischinger et al., 2009; Caetano et 
al., 2011b). 
 Figure 5: Representation of biosynthetic gene clusters involved in the production of lichenicidin 
(Caetano et al. 2011a). 
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Both unmodified forms of lichenicidin, encoded by licA1 and licA2, possess a leader 
peptide with 42 and 34 amino acids respectively (Begley et al., 2009). A double-Gly motif 
was identified as the proteolytic site for LicT. In lichenicidin propeptide sequence a high 
number of Ser and Thr especially at the N-termini is observed (Begley et al., 2009; 
Caetano et al., 2011a).  
Our group developed the first heterologous expression system for a class II two-
component lantibiotic gene cluster in E. coli. This system was developed for the 
lichenicidin produced by B. licheniformis I89. This allowed the production of new 
lichenicidin variants and permitted the identification of essential residues for biosynthesis 
and antibacterial activity. In addition, it enabled to confirm the structure of the peptides, 
previously proposed (Caetano et al., 2011a). At the structural level (Figure 6), the first 
amino acid of both Bliα and Bliβ undergoes dehydration, followed by a deamination 
resulting in a 2-oxobutyryl (Obu1) residue. The same was also described for other 
lantibiotics such as Pep5 and Lactβ peptides (Caetano et al., 2011a). A study performed by 
Caetano et al. (2011a) described an Ala-scan for all positions containing Ser and Thr 
residues, which confirmed that Ser30 escapes dehydration in Bliα and also Thr10, Ser21 
and Ser30 remain unmodified in the Bliβ. Also, it was found that in Bliα, Ser5 with Cys7 
are the amino acids involved in the Bliα A-ring formation and in Bliβ, Ser7 is the residue 
involved in Lan formation with Cys11. Moreover, the pattern of lanthionine rings 
(especially B, C, and D rings) seems to be conserved among two-component lantibiotics, 
indicating their importance at the biological activity level. Mersacidin has a Glu17 residue 
that is essential for binding to the lipid II target. In lichenicidin Bliα, the homologous 
Glu26 in also important for bioactivity. 
 
Figure 6: Proposed structures of Bliα and Bliβ peptides of the lichenicidin complex (Caetano et al. 2011a). 
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1.2.2 Mechanism of action of lantibiotics 
 
Lantibiotics have different mechanisms of action. While, some bind to lipid II and 
inhibit the cell wall biosynthesis, others attack the membrane of bacteria forming pores. 
Some compounds have a double mode of action that combines inhibition of 
peptidoglycan biosynthesis by binding and dislocation of lipid II with pore formation in 
bacterial membranes. All functions can be combined in a single molecule (e.g. Nisin) or 
can be implemented in a combination of two functionally specialized peptides (e.g. 
Lacticin 3147). In two-peptide lantibiotics, it is believed that the mechanism of action 
involves the interaction of both peptides. It is thought that α-peptide binds to lipid II on 
the wall and then forms a complex with the elongated β-peptide. Subsequently, the β-
peptide forms an ion-conducing pore in the membrane of the target cell, causing a rapid 
efflux of K+ and phosphate ions inducing an immediate dissipation of the membrane 
potential and hydrolysis of intracellular ATP, leading to cell death. This system can be 
found in lacticin 3147 lantibiotic (Wiedemann et al., 2006; Dischinger et al., 2009; 
Shenkarev et al., 2010). 
It is well known that the lichenicidin complex is active against methicillin-resistant 
Staphylococcus aureus (MRSA), Listeria monocytogenes, Micrococcus luteus ATCC 9341, 
Bacillus subtilis, Enterococcus faecium, Enterococcus faecalis and Haemophilus influenzae 
(Mendo et al., 2004; Begley et al., 2009; Dischinger et al., 2009; Caetano, 2011). It is 
believed that the mechanism of action of lichenicidin should be very similar to that 
previously described for other two-peptide lantibiotics, especially haloduracin and lacticin 
3147. Thus, the α-peptide binds to lipid II and subsequently the β-peptide involved in this 
complex in a 1:1 stoichiometry is likely to interact with the membrane forming pores 
(Shenkarev et al., 2010). 
 
 
 
11 
 
 
 
 
 
 
 
1.2.3 Self-protection of the producer strain 
 
As discussed before, lantibiotics are potent antimicrobials, with a broad range of 
target strains. These substances need to be synthesized and exported from the producer 
strain to the extracellular space. Therefore, the producer strain must defend itself from 
its own product. Consequently, it must have mechanisms of self-protection preventing 
cell death caused by its own bacteriocin, a process called immunity. 
 The producer strain can adopt two types of mechanism: i) individual immunity 
proteins (normally called LanI proteins), or ii) an ABC transporter (usually composed by 
two or three subunits called LanFE(G)). It is also possible that both mechanisms can act in 
combination (e.g Nisin). A third member of the immunity system, LanH can also be 
present. This protein was thought to act as an ancillary protein for the assembly of a 
functioning ABC transporter (Figure 8) (Draper et al., 2008; Dischinger et al., 2009). The 
ABC transport systems are one of the most abundant families of proteins in nature. They 
Figure 7: Proposed structures of Mersacidin, halodurain (Halα and Halβ) and lacticin 3147 (Ltnα and Ltnβ) 
(Caetano et al. 2011a). 
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are constituted by an ATPase domain of bind and perform the hydrolysis of ATP to ADP. 
The proteins of the system are composed by two hydrophobic integral membrane 
domains (IM) where the ligation of the substrate occurs and two hydrophilic cytoplasmic 
domains carrying the ABC system where the ATP binds and is hydrolysed, proceeding to 
the import and export of the molecules. The LanI peptide can be found attached to the 
membrane or free in the outside of the cell. LanI can also function as a single peptide or 
can form a homodimer. Usually both forms bind to the lantibiotic and forms aggregates. 
In the NisI case, it is believe that NisI binds and aggregates with nisin preventing the 
formation of pores (Draper et al., 2008). 
Regarding the two-component lantibiotics, there is little information about their 
immunity systems. In this type of peptides it is not apparent whether they protect cell 
against one particular peptide or both. Instead, it is thought that they prevent the 
interaction of the two peptides, thus reducing their activity and potency (Draper et al., 
2008). Regarding lichenicidin self-protection it is known that the licFGEHI immunity genes 
are not essential for peptide production when it is produced in the heterologous system 
in E. coli (Dischinger et al., 2009; Caetano et al., 2011b). 
 
 
 
 
Figure 8: Structural organization of the two type mechanisms of immunity system. LanF functions as an ATPase, while 
LanE/G form the membrane spanning domain of the ABC transporter (a). The LanI peptide can be found attached to the 
membrane or found free in the supernatant as observed with NisI (b). LanI peptides can also be integral membrane 
proteins with three putative transmembrane regions (c) (Draper et al. 2008). 
13 
 
 
 
1.3 Directed Evolution 
 
Natural evolution produces a large number of proteins and enzyme variants, and 
these variants exhibit their function with high specificity and efficiency. These changes 
have adjusted species only to perfect their physiological role and therefore their 
specificity and stability are usually far away from what biotechnology industry needs 
(Field et al., 2007, 2010; Labrou, 2010). Directed evolution is an in vitro fast process for 
generation of new variants of proteins, enzymes, metabolic pathways or even entire 
genomes variants with new and desired properties (Field et al., 2007; Labrou, 2010). 
Directed evolution process was a powerful tool especially for proteins whose crystal 
structures are unavailable or for those which relationships between structure and 
function continue to be recognized. Thus, a successful directed evolution experiment 
implies an efficient library construction (that must be as large and diverse as possible) and 
a robust high-throughput screening of the mutant library (Figure 9) (Brakmann & 
Schwienhorst, 2004; Vanhercke et al., 2005; Wang et al., 2006). 
Random mutagenesis is a strategy where random point mutations are introduced 
into targets (e.g. gene, whole genome). This methodology is usually used to create 
mutant libraries for protein engineering applications, with the ultimate goal of generating 
protein variants with desired properties. The selection of the appropriate method for 
random mutagenesis, takes into account the most important performance criteria which 
include an impartial mutation spectrum and a controllable mutation frequency. There are 
a lot of different techniques that can be applied, as enzymatic strategies that explore the 
properties of DNA modifying enzymes like DNA polymerase, in “error-prone” PCR. Other 
alternatives are the purely chemical methods and the cell based mutagenesis methods, 
which are based on the increase of errors during DNA replication (Brakmann & 
Schwienhorst, 2004; Rasila et al., 2009; Labrou, 2010). However, the most common 
technique is random PCR mutagenesis due to its simplicity and versatility. This technique 
has a mutation frequency of around 10 % per nucleotide position. Changing some PCR 
conditions allows the rate of the mutation to be adjusted to the appropriate level 
(Brakmann & Schwienhorst, 2004).  
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Usually, the experimental cycle of directed evolution using random mutagenesis 
consists in some important steps. At the beginning, a DNA sequence that encodes the 
desired protein is chosen and this sequence is submitted to a step of mutagenesis, to 
introduce some random point mutations, followed by the introduction of the mutated 
DNA in an expression vector that is incorporated into a host cells. Then, a screening to 
select the transformants that contain the encoded sequence as well as the desired 
properties is performed. In the end, the selected sequence can be re-amplified and the 
cycle can be repeated again for further improvement if necessary (Figure 9) (Labrou, 
2010). 
 
 
 
 
 
 
 
 
 
 
1.3.1 Random mutagenesis applied to the bioengineering of 
lanthipeptides  
 
Lanthipeptides have a ribosomal origin that turns it easier the application of 
strategies to produce modifications on the peptide, enabling the creation of new variants 
with altered biological, chemical and physical properties. Such modifications can be 
generated by site-directed mutagenesis or by random mutagenesis (Field et al., 2007, 
Figure 9: Experimental steps of an in vitro directed evolution process. A parent DNA sequence encoding for a 
desired protein is chosen. Sequence diversity is created through a random mutagenesis step, (the symbol * 
represents point mutation). The library of DNA sequences is ligated into an expression vector. Recombinant 
clones are transformed into host cells, and the protein variants are expressed. A screening or selection 
procedure is employed next to isolate the transformants (Labrou, 2010). 
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2010). The site-directed mutagenesis ensures the substitution of a specific single amino 
acid, however it is time consuming. Thus, random mutagenesis has been an appealing 
alternative. However, few lantibiotics have been subjected to this process. For instance, 
for class I lanthipeptides this approach was used only for nisin and for class II was used for 
lacticin 3147.  
A random mutagenesis library was performed to nisin and around of 8000 mutants 
were screened and only one variant exhibited enhanced efficacy against both Gram-
positive and Gram-negative bacteria (Field et al., 2012). 
Regarding Lacticin 3147, a two-component lantibiotic like lichenicidin, the random 
mutagenesis library was performed by mutating simultaneously both structural genes. 
After the construction of this library, around 1500 mutants were screened to identify 
mutations with impact on the bioactivity and mutations involved in improved bioactivity 
were not identified. In addition, it was confirmed the importance of some residues that 
caused a decrease and abolishment of the bioactivity (Field et al., 2007, 2008). 
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2. Objectives 
 
 Bioengineering of lichenicidin can be important to better understand its biosynthesis 
and its mechanism of action. Also, it would be important to obtain new variants with 
improved bioactivity. An attractive technique to generate these variants is the use of 
random mutagenesis. Thus, the objectives of this work were: 
 
i) Construction of a heterologous expression system of lichenicidin in E. coli 
allowing white and blue selection;  
ii) Generation of two independent libraries by random mutagenesis for each of 
the lichenicidin peptides (Bliα and Bliβ); 
iii) Identification of mutations with negative and positive impact on the bioactivity 
of the peptides produced. 
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3. Material and Methods 
 
The following flowchart shows the experimental procedures employed for 
establishment of the white and blue selection system, the generation of mutants to both 
peptides of lichenicidin and the selection of these mutants (Figure 10).  
 
 
Figure 10: Schematic representation of the workflow of the present work. 
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3.1 Vectors and strains 
 
In this study, different strains of E. coli of which some comprising fosmid and 
plasmids with parts of the lichenicidin gene cluster were used. The following tables show 
the strains and vectors used. 
 
 
Table 3: Plasmid and fosmids used in this study, MW refers to the molecular weight of the respective vector. 
Strain Description/ Genotype Phenotype Source 
E. coli DH5α 
recA1relA1gyrA96deoRnupGΦ80dlacZΔM15 
Δ(lacZYAargF)U169, hsdR17(rK- mK+), λ– 
- MUL 
E. coli Mach1 
F- φ80(lacZ)∆M15 ∆lacX74 hsdR(rK-mK+) 
∆recA1398 endA1 tonA 
- InvitrogenTM 
E. coli Top10 
F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 
nupG 
- InvitrogenTM 
E.coli Blic5ΔA1 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA1 fosmid (pLic5 with licA1 gene 
deleted)  
CmR 
(Caetano, et al., 
2011a) 
E.coli Blic5ΔA2 
E. coli BL21-Gold(DE3) containing the 
pLic5ΔA2 fosmid (pLic5 with licA2 gene 
deleted)  
CmR 
(Caetano et al., 
2011a) 
M. luteus ATCC 
9341 
Indicator strain - MUL 
Table 2: List of general strains used in this study. ATCC (American Type Culture Collection); MUL (University of Lisbon 
Microorganims Collection). 
Vectors Source MW Selective 
marker Description 
pUC19a Fermentas 2.7Kb AmpR 
 
High copy number E. coli 
plasmid; region of E. coli lac 
operon, promoter Plac, lac 
repressor binding site and the 5’-
terminal part of the lacZ gene 
encoding the N-terminal 
fragment of beta-galactosidase, 
includes NcoI and NheI 
restriction sites. 
pLic5 This group 34.8Kb CmR 
pCC2FOS fosmid containing all 
the  the genes for lichenicidin 
production. 
pLic5ΔA1ΔA2 This group 34.1Kb CmR 
 
pLic5 fosmid with all the genes 
for lichenicidin production, 
except the structural genes A1 
and A2. 
pUClicA1 This group 3Kb AmpR 
pUC19a plasmid with the licA1 
gene into the MCS. 
pUClicA2 This group 3Kb AmpR 
pUC19a plasmid with the licA2 
gene intro the MCS. 
pUClicA2ST This group 3Kb AmpR 
pUC19a plasmid with the licA2 
gene. Instead of the TAG stop 
codon it has the TAA stop codon. 
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3.2 Media and growth conditions 
 
E. coli strains were grown in Luria-Bertani agar (LA) plates at the appropriated 
temperature. Whenever extraction of DNA was necessary, Luria-Bertani broth (LB) was 
used for general liquid growth of E. coli strains at 37 oC, and at 180 rpm. For lichenicidin 
production M medium was used that consisted of: 10 g/L of NaCl, 10 g/L of trytptone, 5 
g/L of yeast extract, 10 g/L of KH2PO4, pH was adjusted with NaOH to 6.5 (Mendo et al., 
2004). For solid-based production assays M medium was supplemented with 20 g/L of 
agar prior to autoclaving. Micrococcus luteus ATCC 9341 was used as the indicator strain 
in the bioassay to evaluate lichenicidin production. The strain was maintained in tryptic 
soy agar (TSA), and liquid cultures were performed in tryptic soy broth (TSB) at 37 oC and 
180 rpm. For routine bioactivity screening, the selection was performed in LA plates 
containing the following antibiotic concentrations: chloramphenicol (Cm), 12.5 µg ml-1 
and ampicillin (Amp), 100 µg ml-1. 
3.3 Construction of plasmids plicA1, plicA2 and plicA2ST 
 
In this study, three plasmids were used. The first plasmid contained the structural 
gene for licA1 (plicA1). A second plasmid contained the gene for the licA2 production 
(plicA2). However, when the latter plasmid was used, it was observed that colonies that 
should have a white color, presented a bluish color that may correspond to  false positive 
clones. One possible justification for this color could result from a deficient stop codon 
that is less favorable in E. coli strains. Thus, it was necessary to construct another plasmid 
containing the licA2 gene and where TAG stop codon was replaced by TAA a more 
efficient stop codon for E. coli.   
The amplification of licA2 was performed by NZYProof DNA Polymerase (Nzytech) in a 
25 µL reaction containing 0.25 µL of dNTPs mix (0.2 mM), 2.5 µL of Reaction buffer (10X), 
0.75 µL of each primer (10 pmol/µL), 0.01-0.5 µg of total DNA of B. licheniformis I89 and 
0.25 µL of NZYProof DNA polymerase (0.625 U). The primers used are listed in Table 4. 
The PCR program had an initial denaturation step, 95 oC for 2 min, followed by a 
denaturation step 95 oC for 30 seg, annealing at the specific temperature (Table 4) and 
extension at 72 oC for a given time (Table 4). These 3 last steps were repeated 30 times 
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followed by a final extension step at 72 oC for 5 min. PCR product was analyzed by 
electrophoresis 1 % agarose gel (Appendix 1) and later purified by NZYGelpure kit from 
Nzytech according to the manufacturer’s instructions (Appendix 2). DNA concentration it 
was determined using Qubit® (Appendix3). 
 
Table 4: List of primers used to amplify the licA2 and respective sequences, annealing temperatures, expected size of 
each amplicon, the extension time for each target gene and the respective restriction enzyme. 
 
 
To introduce the amplified licA2ST fragment into the vector pUC19a, it was necessary 
to make a digestion of both elements before ligation. Plasmid digestion was performed in 
a final volume of 20 µL containing 600 ng of pUC19a DNA. PCR product digestion was 
carried out in a final volume of 40 µL with 1000 ng of licA2ST. In the plasmid reaction, 1 µL 
of each enzyme (NcoI and BamHI) and 2 µL of the 10X FastDigest Buffer (Thermo 
Scientific) where used. In the reaction of the PCR product, the volumes employed were 
twice as those used in plasmid reaction. The digestion was performed at 37 oC for 5 min, 
and followed by purification using the NZYGelpure kit from Nzytech according to the 
manufacturer’s instructions (Appendix 2). 
Ligation reaction was performed in a total volume of 20 μL containing 50 ng of 
pUC19a DNA, 150 ng of licA2ST DNA, 1X T4 DNA ligase buffer and 1 μL of T4 DNA ligase 
(Fermentas). Reaction was incubated at 22 oC for 30 min on a thermocycler (BioRad) and 
posteriorly conserved at -20 oC until further use. 
Competent cells were prepared as described in 3.7.1 and transformation was 
performed according to 3.7.2.  
 
Primer Name 
Primer sequencing 
(5’→3’) 
Annealing 
Temperature 
( oC) 
Expected 
amplicon (bp) 
Extension 
Time 
Restriction 
enzyme 
Comp_licA
2_BamHI_
Rv 
TATGGATCCCTAGCAT
CGGCTTGTACAC 
59 300 60 seg 
BamHI 
Comp_licA
2_NcoI_Fw 
TATCCATGGCTATGAA
AACAATGAAAAATTC 
NcoI 
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3.4 Development of heterologous expression system of 
lichenicidin in E. coli. 
 
3.4.1 Blue and white selection of lichenicidin producing strains  
 
In all the 3 E. coli strains used (E. coli Top10, E.coli DH5α and E.coli Mach1) the fosmid 
containing all the genes for lichenicidin production, with exception of the structural 
genes, was introduced (plic5∆A1∆A2). The fosmid was extracted by alkaline lysis 
(Appendix 4) and transformed by heat-shock in chemically-competent cells (see 3.7.1 and 
3.7.2). 
 
Table 5: List of primers used to amplify licT and licP and respective sequences, annealing temperatures, expected size of 
each amplicon and the extension time for each target gene 
 
Fosmid incorporation was confirmed by PCR. The amplification reaction was 
performed with Taq DNA polymerase (Nzytech) as described in Appendix 1 and using the 
primers and annealing temperatures indicated in Table 5. PCR products were analyzed by 
electrophoresis 1 % agarose gel (Appendix 1). 
Subsequently, each strain containing the pLic5ΔA1ΔA2 fosmid (E. coli Top10 
pLic5ΔA1ΔA2, E.coli DH5α pLic5ΔA1ΔA2 and E.coli Mach1 pLic5ΔA1ΔA2) was transformed 
with a plasmid containing one of the structural genes (plicA1, plicA2 and plicA2ST). These 
plasmids were extracted with the Plasmid DNA Kit from KOMABIOTECH as described in 
Appendix 4. In this step were used the strains E. coli Mach1 plicA2ST to extract the 
plasmid containing the gene encoding licA2 with the new stop codon (plicA2ST), E. coli 
DH5α plicA1 to extract the plasmid containing the gene encoding licA1 (plicA1) and E. coli 
DH5α plicA2 to extract the plasmid containing the gene encoding licA2 (plicA2). The 
Primer Name Primer sequencing (5’→3’) 
Annealing 
Temperature 
(oC) 
Expected 
amplicon (bp) 
Extension Time 
Comp_licT FW 
AAGGAGATATACATATGTTT
TTTCATAAGACACCGTT 
52 3600 
3 min and 50 
seg 
Comp_licP RV 
GGTGGTGGTGCTCGAGTCA
CTCCTTGTTCATCATTTTC 
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strains were inoculated in 5 mL of LB medium supplemented with Amp and grown 
overnight at 37 oC and 200 rpm.  
 
Table 6 List of primers used to amplify the MCS of pUC19a and respective sequences, annealing temperatures, expected 
size of each amplicon and the extension time for each target gene 
 
After transformation cells were spread on LA plates supplemented with Cm, Amp and 
X-Gal and were incubated overnight at 37 oC. A PCR was employed to confirm the 
presence of the desired plasmid in the transformed cells. Only white clones were selected 
for colony-PCR. The amplification reaction was performed with Taq DNA polymerase 
(Nzytech) as described in Appendix 1, using the annealing temperatures indicated in 
Table 6. PCR products were analyzed by electrophoresis 1 % agarose gel (Appendix 1). 
In order to confirm if the obtained strains were producing the expected peptides, a 
colony-bioassay was performed. Tis bioassay was performed, in a Petri dish containing 
TSA and M. luteus (OD600 reached 0.02) where each strain was inoculated together with 
the complementary strain (Bli5ΔA1 or Bli5ΔA2). The aim of this assay is to verify the 
presence of inhibition halos between the two strains after incubation overnight at 37 oC. 
 
3.4.2 Comparison of Bliβ and Bliα production by the different 
strains 
 
In order to select the appropriate strain and temperature to construct and screen the 
final library, the comparison of production in agar medium was performed.  
 
 
 
 
 
 
Primer Name Primer sequencing (5’→3’) 
Annealing 
Temperature 
(oC) 
Expected 
amplicon (bp) 
Extension Time 
Puc19 FV GTAAAACGACGGCCAGT 
56 300 45 seg 
Puc19 TC RV CTTCCGGCTCGTATGTTG 
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3.4.2.1 Quantification by colony-bioassay 
 
In this assay, 20 mL of agarized M medium was inoculated with one colony of each 
strain. This was performed in duplicate and one set was incubated overnight at 37 oC and 
the other at 30 oC. After incubation, the plates were exposed to UV radiation for 15 min 
and overlaid with 15 mL of TSA containing M. luteus at a final OD600 of 0.02 and 1.875 µL 
of the respective supernatant prepared as described below (3.4.2.2). The inhibition zones 
were measured after an incubation period of 16-18 h, at 37 oC. The same assay was 
performed with E. coli Mach1pLic5, E. coli Top10pLic5 and E. coli DH5αpLic5 strains as 
controls. Since these strains have the entire gene cluster for the production of 
lichenicidin, it was not necessary to add the supernatant in the medium. 
 
3.4.2.2 Preparation of supernatants  
  
These generated strains can only produce one of the peptides, either the Bliα (if they 
have plicA1) or Bliβ (if they have plicA2 or plicA2ST) and therefore they do not exhibit 
activity against M. luteus unless they are supplemented with the complementary peptide 
in the agar medium (either beta or alpha respectively) Thus, the peptides were supplied 
as supernatants: the Bliα as supernatant of the E. coli Blic5ΔA2 strain and the Bliβ as 
supernatant of E. coli Blic5ΔA1 strain. To obtain these supernatants, E. coli Blic5ΔA1 and 
E. coli Blic5ΔA2 were pre-cultured in LB medium supplemented with 12.5 μg/mL of Cm, at 
37 oC, 180 rpm, overnight. In the following day, 300 µL of this pre-cultured were 
inoculated into 50 mL of M medium. After 24 h at 37 oC, 180 rpm, the culture was 
centrifuged twice at 10 000 rpm for 5 min. The supernatant was collected and filtered 
through a 0.02 µm nitrocellulose filter and stored at -20 oC until further use. 
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3.5. Random mutagenesis library of Bliα and Bliβ 
peptides  
 
3.5.1. Construction of the library  
 
 Random mutagenesis required purified plicA1 and plicA2ST DNA which was 
performed as described in Appendix 4. GeneMorph II Random Mutagenesis kit (Agilent) 
was used to perform random mutagenesis on the extracted plasmids. The kit contains the 
Mutazyme II that allows a mutation rate of 1 to 16 mutations per kb. The desired 
mutation rate can be controlled by varying the initial amount of target DNA in the 
reaction or by changing the number of amplification cycles. To introduce a maximum of 
1.35 base changes on the cloned fragments, a dilution of pDNA was performed to obtain 
an initial amount of the target gene of 100 ng. The amplification reaction was performed 
in a 50 µL total volume and the primers used (Table 7) were mixed together, in order to 
obtain a final concentration of 250 ng/μL of each primer. 0.5μL of primer mix was added 
to the reaction along with, 1 μL of dNTPs mix (25 mM), 2.5 U of Mutazyme II DNA 
polymerase and 9.09 μL of target DNA was used at a final 20 ng/μL concentration. The 
amplification initial denaturation step was performed at 95 oC by 2 min, followed by 30 
cycles of denaturation at 95 oC for 30 sec, annealing at 59 oC and extension at 72 oC for 1 
min. The final extension step was performed at 72 oC for 10 min. 
The amplificated product was treated with 1 µL of Dpn1 for 1h at 37 oC. 
Subsequently, the PCR product was run in an agarose gel and further purified with 
NZYGelpure kit (Nzytech; Appendix 2).DNA concentration was determined using Qubit ® 
(Appendix 3). 
Then the PCR product (1000ng) and the plasmid pUC19a (1000ng) were digested with 
the appropriate enzyme. In both reactions 1 µL of each restriction enzyme was added 
(BamHI and NcoI) to the reaction together with 1X FastDigest Buffer (Thermo Scientific). 
The mixture was incubated at 37 oC for 30 min. Both reactions were subsequently purified 
using the NZYGelpure kit (Nzytech; Appendix 2).  
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Table 7: Primers used to amplify licA1 and licA2 for random mutagenesis method and colony-PCR screening. Primer 
sequence, annealing temperatures, expected size of each amplicon and the extension time for each target gene was are 
also included. 
 
Ligation reaction was performed in a final volume of 20 µL, containing 16.8 ng of 
purified and digested PCR product, and 50 ng of pUC19a, 2 µL of 1X T4 DNA ligase buffer 
and 1 μL of T4 DNA ligase (Fermentas). The reaction was incubated at 22 oC for 2h on a 
thermocycler (BioRad) and desalted using a membrane MFTM – Membrane filters 
(Millipore) placed in a surface of a petri dish containing distilled water during 30 min. 
Finally, 5 µL of each ligation were mixed with 50 µL of E. coli Mach1ΔA1ΔA2 
electrocompetent cells (See 3.7.3). The electroporation was then performed using 1 mm 
gap electroporation cuvettes using the MicroPulser Electroporator (BioRad) (See 3.7.4). 
995 µL of LB were added to the cuvettes and after 1 hour at 37 oC, the culture was 
distributed in 9 tubes containing 100 µL of the culture and 50 µL of glycerol at 45 %. The 
tubes were then stored at -20 oC until further use. When the culture was necessary, 10 µL 
of culture together with 90 µL of LB were spread in LB agar plates containing 12.5 µg/mL 
of Cm, 100 µg/mL of Amp and 100 µg/mL X-Gal. 
 
3.5.2 Screening of the library and bioassay 
 
Approximately 4000 white clones from each library were picked into LA plates 
supplemented with Amp and Cm. The plates were incubated overnight at 37 oC, in order 
to further test their antibacterial activity. 
The bioactivity of each clone was then evaluated by colony-bioassay. Square plates 
were prepared with 30 mL of agarized M medium. 11 clones and the respective control 
(E. coli Mach 1∆A1∆A2 pLicA1 and E. coli Mach 1∆A1∆A2 pLicA2ST) were selected and 
Primer Name Primer sequencing (5’→3’) 
Annealing 
Temperature 
(oC) 
Expected 
amplicon (bp) 
Extension Time 
Puc_mut_Rv 2 
GGTACCCGGGGATCCTT
A 
59 300 1 min 
Puc_mut_Fw 
GAA ACA GCC ATG GCT 
ATG 
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incubated in each plate overnight at 37 oC. After incubation, the plates were exposed to 
UV radiation for 15 min. Finally colonies were overlaid with 15 mL of TSA with M. luteus 
at a final OD600 of 0.02 and 3.125 µl of the respective supernatant (see preparation at 
3.4.2.2). The visualization of inhibition areas was possible after overnight growth at 37 oC. 
These selected clones were grouped into 4 distinct groups; null activity (NA), very low 
activity (VLA), reduced activity (RA) and high activity (HA) always in comparison whit the 
control. In order to confirm the higher activity of some clones, a dot-colony-bioassay was 
performed. To make this dot-colony-bioassay, each clone was pre-cultured into 3 mL of 
LB medium supplemented with 12.5 μg/mL of Cm and 100 µg ml-1 of Amp and grown 
overnight, at 37 oC, 180 rpm. 30 µL of this pre-cultured was inoculated into 3 mL of M 
medium and incubated at 37 oC, 180 rpm, overnight. After 16-18 h, 2 µL of each clone was 
placed into the plate containing agarized M medium. After overnight incubation at 37 oC 
the plates were exposed to UV radiation for 15 min. Finally colonies were overlaid with 15 
mL of TSA with M. luteus at a final OD600 of 0.02 and 3.125 µl of the respective 
supernatant.  
After the confirmation of some bioactivities, around 30 clones of each group were 
sequenced, following the plasmid extraction (see Appendix 4). 
 
3.6 LC-ESI-MS analysis 
 
3.6.1 Extraction and analysis of the peptides 
 
Clones having mutation that do not involve amino acids essential to the bridge 
formation were selected to a LC-ESI-MS analysis. To obtain this extracts, a pre-inoculum 
of each clone in 5 mL of medium M, with Cm at 12.5 µg ml-1 and Amp at 100 µg ml-1 was 
performed and clones were grown at 37 oC, 180 rpm, overnight. In the next day, the OD 
of each culture was measured. If the OD it was similar, it was not adjusted. If not, needs 
to be adjusted. 300 µL of which culture was used to seed the 30 mL of medium M and 
grow for 24 hours at 37 oC. On the following day, the culture was transferred to a falcon 
and 5 ml of Butanol was added. After 1 hour at 180 rpm, a centrifugation step was 
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performed at 10 000 rpm by 5 min. 1 ml of the upper phase was collected, placed in a 1,5 
tube and a evaporation step at 50 oC was performed.  Tubes were stored at -20 oC until be 
analyzed. 
The LC-ESI-MS analysis was performed according to Caetano et al. (2011a). 
 
3.7 Transformation 
 
3.7.1. Preparation of competent cells by calcium-chloride 
method 
 
The strains were inoculated in 5 mL of LB medium and grown overnight at 37 oC and 
200 rpm. After 16-18h, 1 mL of each culture was used to inoculate a new erlenmeyer 
containing 100 mL of LB, incubated at 37 oC and 200 rpm until OD600 reached 0.3. At this 
stage, the culture was transferred to a 50 mL sterile falcon and centrifuged at 7 000 xg, 4 
oC for 2 min. The supernatant was discarded and the cells suspended in 50 mL of 0.1M 
MgCl2 solution, followed by another centrifugation step at 7 000 xg, 4 oC for 2min; then 
the supernatant was discarded. The pellet was suspended in 50 mL of 0.1M CaCl2.The 
suspension was incubated 20 min on ice and centrifuged at 7 000 xg at 4 oC for 2 min 
again, the supernatant was discarded and the pellet suspended in 1 mL of 0.1 M CaCl2 
with Glycerol 15 % solution. Aliquots of 100 µL were distributed into several tubes, 
properly identified and stored at -80 oC until use. 
 
3.7.2. Transformation by heat-shock 
 
Two aliquot of 100µL of each previously prepared competent cells were thawed on 
ice and 5µL of the vector were added to the tube. The mixture was incubated on ice for 
15 min and transferred to 42 oC for 45 sec. The tube was immediately placed on ice for 2 
min and 1 mL of LB medium was added. The cells were then grown for 1 hour at 37 oC, 
200 rpm; the culture was centrifuged at 5 000 rpm for 1 min to collect cells; most of 
supernatant was discarded and the pellet was suspended in the remaining supernatant. 
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Finally the cells were spread on LB agar plates containing the appropriate antibiotics and 
incubated at 37 oC, overnight. 
 
3.7.3. Preparation of competent cells for electroporation  
 
The desired strain was inoculated in 10 mL of LB medium supplemented with the 
appropriate selective marker and incubated at 37 oC, 180 rpm, and overnight. 1.5 mL of 
this overnight culture were used to inoculate 125 mL of fresh 2XYT broth containing the 
appropriate selective marker. The culture was grown in the same conditions until OD600nm 
of approximately 0.4. The culture was then centrifuged at 5000 rpm for 5 min and 4 oC. 
The supernatant was discarded and the pelleted cells were resuspended in 30 mL of cold 
10 % glycerol by gently mixing. This procedure was repeated again. After centrifugation, 
the cells were suspended in 1 mL of cold 10 % glycerol and distributed in 1.5 mL tubes. 
These competent cells were kept at 4 oC until use. This procedure was always performed 
in the same day of the transformation.  
 
3.7.4 Transformation by electroporation  
 
50 µL of cells were mixed with 5 µL of DNA and maintained on ice. The mixture was 
transferred to a 1 mm gap ice-cold electroporation cuvette and a single pulse was applied 
using the Ec1 program (200Ω, 25µF and 2.5RV) in the MicroPulser Electroporator 
(BioRad). Immediately, 950 µL of LB medium were added to the cuvette and the 
suspension was incubated at 37 oC for 1 hour at 180 rpm. The culture was then spread in 
LB agar plates containing the appropriated antibiotics. The plates were incubated at 37 oC 
overnight. 
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4. Results and Discussion 
4.1 Selection of a white/blue system for library 
construction 
 
The trans complementation system available for the production of lichenicidin in E. 
coli did not allow white/blue selection. This is because E. coli BL21Gold(DE3) possesses 
the lacZ gene in its chromosome. Additionally, the plasmid used (pET-24a) in that system 
did not contain this gene. Thus, in the present study, the pLic5ΔA1A2 fosmid (comprising 
the entire lichenicidin gene cluster, except licA1 and licA2 structural genes) was 
transformed into 3 different E. coli strains: DH5α, TOP10 and Mach1T1, all of them 
permitting white/blue selection. Then, each of the genes licA1 and licA2, was amplified 
and cloned in the multiple cloning site of pUC19a plasmid, disrupting the lacZ gene. 
However, it was found that the colonies of all the strains containing the plicA2 plasmid 
still express the blue phenotype, which was not observed with the plicA1 strains (Figure 
11). Nucleotide sequences of both structural genes cloned, revealed that in licA1 the stop 
codon was TAA, whereas in licA2 it was TAG. These were the original stop codons, i.e., 
from Bacillus licheniformis I89. In E. coli, TAA corresponds to “ochre” codon and TAG 
corresponds to the “amber” codon, which results in a weaker termination. Hence, we 
replaced the TAG codon by TAA in the plicA2, originating the plicA2ST plasmid. After this 
change, the colonies presented a whiter phenotype, as expected. Therefore, it was 
concluded that the use of “amber” stop codons in these systems should be avoid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Colonies color when the original STOP codon is 
present. 
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Afterwards, the agar-based production of lichenicidin peptides by the three strains 
was evaluated by colony-bioassay at two different temperatures: 30 oC and 37 oC (Figure 
12 and 13). It was found that the inhibition zones were greater at 37 oC, for both 
peptides. Therefore, this was the temperature chosen for the screening of the random 
mutagenesis library. For Bliα, the levels of production do not seem to be influenced by 
the nature of the strains used, since no major differences in inhibition were observed 
between DH5α, TOP10 and Mach1T1 strains (Figure 12). For Bliβ, a comparison of the 
strains with plicA2ST (ochre stop codon) and plicA2 (amber stop codon), a slight increase 
in the production can be observed for the first, especially for Mach1 and DH5α (Figure 
13). Accordingly, any of these two E. coli strains can be used for the library construction. 
Finally, Mach1 was selected because DH5α colonies containing both pLic5ΔA1A2 and the 
plicA2ST still exhibited a shade of blue color. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Radius size of colony-bioassay of the three E.coli strain 
producing Bliα at 30 oC and 37 oC. 
Figure 13: Radius size of colony-bioassay of three E. coli strains producing Bliβ at 30ºC and 37ºC, with plasmid plicA2ST (A) 
and plicA2 (B). 
A 
B A 
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4.2 Screening of the random mutagenesis library 
 
The screening of the two libraries, was performed by colony-bioassay. Clones with 
different bioactivity from that of the control were selected. The clones were grouped into 
4 distinct groups: null activity (NA), very low activity (VLA), reduced activity (RA) and 
higher activity (HA) when compared to control (Figure 14). 
 
 
Considering the Blicα library, around 4.5 % of the clones showed null activity, 2.6 % 
present very low activity, 2.2 % reduced activity and 0.5 % higher activity. The percentage 
for Blicβ library was very similar since around 5.1 % clones showed null activity, 1.4 % very 
low activity, 3.8 % reduced activity and 0.58 % of the clones present higher activity. To 
confirm a high producing phenotype, clones exhibiting higher activity were tested by a 
dot-colony-bioassay. This method is more reliable since it is more accurate and the 
number of inoculated cells is identical between samples. This assay revealed that none of 
the clones showed improved activity. 
Clones belonging to NA, RA and VLA groups were selected for sequencing of the 
structural gene, to determine the mutations responsible for those phenotypes. The 
antibacterial activity of all of these clones was confirmed prior to sequencing, by colony-
bioassay for colonies with very low and null activity and by dot-colony-bioassay for 
mutants showing reduced activity. So, for the Bliα library, 45 clones with the NA 
phenotype, 30 from the RA group and 43 belonging to VLA group were analyzed. For Bliβ 
library, 43 colonies of the NA group, 30 from RA and 30 with VLA phenotype were 
analyzed. The results showed that the structural gene of numerous clones with null 
a) b) d) c) 
Figure 14 Different classification of the strains with the mutated genes. a) clones with null activity (NA),  b) 
clones with very low activity (VLA), c) clones with activity reduced to 50 % comparing to the control (RA),  d) 
clones with higher activity (HA) and e) clones with no mutated genes (control). 
 
e) 
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activity had premature stop codons (n=15) and frameshift mutations (n=13). Since these 
mutations prevent the production of the encoded peptides, they will not be further 
discussed. Also, some structural genes (n=26) contained more than one nucleotide 
mutation, responsible for more than two changes in the amino acid sequence of the LicA1 
and LicA2 precursor peptides. In this case, the impact on bioactivity could not be 
attributed to a single change and for this reason these clones will also not be considered 
in this study. 
The mutations identified will be discussed in detail in the following sections. 
 
4.3 Mutations in the leader sequence of Bliα 
 
The leader peptides of Class II lantibiotics terminate with a double-Gly motif like Gly-
Gly/Gly-Ala/Gly-Ser. This motif plays an essential role in the cleavage of the leader 
sequence since it is believed that the protease domain of the LanT protein recognizes it 
(Mcauli et al., 2001). In this library, only two mutations were found in the leader peptide 
of LicA1, both affecting the double-Gly motif (Figure 15). In one clone, the second Gly 
(G44) residue of the normal GG-motif was replaced by a Cys and exhibited no bioactivity. 
This suggests that the protease (LicT) is unable to remove the leader sequence of the 
mutated peptide. This was also observed for mutacin II and lacticin 481. In vitro studies of 
these two lantibiotics, demonstrated that mutations on the double-Gly motif result in 
fully dehydrated and cyclized peptides, however proteolysis by LctT was completely 
inhibited (Ihnken et al., 2008; Patton et al., 2009). The other mutation identified was the 
substitution of the first Gly amino acid (G43) by a Glu. Interestingly, in this clone, a 
reduction to half of the bioactivity, in comparison to the control, was observed. This 
result was surprising because the G43E mutation should prevent the removal of the Bliα 
leader peptide and in this situation, the peptide would be inactive. Thus, further work 
should be performed to fully understand if the reduced activity results from less efficiency 
of the proteolysis reaction or differences in the post-translational modifications.  
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4.4 Mutations in the leader sequence of Bliβ 
 
A mutation on the double-Gly motif was also detected in the leader sequence of Bliβ, 
where the second Gly residue was substituted by a Val (Figure 16). As mentioned above 
for Bliα, this alteration would imply the inhibition of the leader peptide proteolysis, 
resulting in a completely inactive peptide. However, although very low, the clone still 
exhibited antibacterial activity, suggesting that albeit at very low levels, a mature peptide 
is being produced. Therefore, more studies will be required to elucidate if the protease 
domain of LicT is actually able to recognize the –GV sequence. Alternatively, it is also 
possible that the phenotype observed is due to the second proteolysis step involved in 
the maturation of Bliβ. 
The other mutations identified were P21T, P21S, H20R and A22E (Figure 16). The 
mutations P21S and P21T resulted in reduction to half of the bioactivity in comparison to 
the control, perhaps because Pro is an essential amino acid for the peptide structure. The 
H20R mutation also resulted in a similar phenotype. However, in this case it was shown 
that the substitution of one positively charged amino acid with other with the same 
nature still affected the efficiency of LicM2 protein, despite at low levels. Therefore, the 
imidazole functional group present in the Arg amino acid should be important for the 
perfect recognition of the leader peptide by the LicM2 modifying enzyme. The last 
mutation identified was A22E. This clone was completely inactive. This was a surprising 
result because so far it was not described that a single mutation in the leader sequence 
could cause a total lack of bioactivity. The LC-ESI-MS analysis of the extracts of the A22E 
clone showed that the fully dehydrated Bliβ peptide was produced (M= 3020 Da). Thus, 
MS/MS analysis should be performed in order to understand which thioether ring was 
affected by this mutation and that lead to its inactivity. 
Figure 15: Mutations detected in the double-Gly motif of Bliα leader sequence. In red 
is the mutation which caused a total abolishment of the bioactivity. In green is the 
mutation which caused a reduction to half of the bioactivity when compared to the 
control. 
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4.4.1 Mutations in the hexapeptide 
 
As already mentioned, the maturation of the Bliβ peptide implies two proteolytic 
cleavages: i) the removal of leader peptide by LicT and ii) the removal of six N-terminally 
located amino acids, commonly designated by hexapeptide (in LicA2: NDVNPE) (Caetano 
et al., 2011a). This extra proteolytic step was also identified for other two-component 
lantibiotics, namely, haloduracin β-peptide (Halβ), plantaricin W β-peptide (Plwβ) and 
cytolysin L and S peptides (CyILL and CyILS) (Booth et al., 1996; Holo et al., 2001; 
McClerren et al., 2006). One possible role of this six N-terminal amino acids is related to 
the protection of the peptide from being degraded in the extracellular environment, since 
proteolysis of the peptide only occurs when it is outside the cell (Cooper et al., 2008). In 
the biosynthesis of Bliβ, the removal of the hexapeptide is performed by LicP protease 
(Caetano et al., 2011a). Along the screening of the Bliβ mutant library, two mutations 
(P41H and E42K) in the hexapeptide causing the reduction of bioactivity to half were 
identified (Figure 17). These alterations involved Pro and charged residues, these amino 
acids are normally important either for secondary structure and/or recognition. Studies 
targeting the hexapeptide are limited. Still, for lichenicidin, it was previously observed 
that the substitutions P41A and E42A did not result in loss of bioactivity, suggesting that 
these residues were not essential for LicP function (Faria, 2011). Yet, Ala is a neutral 
amino acid whereas His and Lys are charged residues.  
 
  
 
 
 
Figure 16: Mutations along of Bliβ 
leader sequence and in the double-Gly 
motif.  In red is the mutation which 
caused a total abolishment of the 
bioactivity. In orange is represented a 
mutation that greatly affected the 
bioactivity and so the mutant showed 
very low bioactivity. In green are the 
mutations which cause a reduction to 
half of the bioactivity when compared 
to the control. 
Figure 17: Mutations identified in the 
Hexapeptide of Bliβ. In green are the mutations 
which cause a reduction to half of the 
bioactivity when compared to the control. 
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4.5 Mutations detected in Bliα  
 
Several types of mutations were identified in the core peptide of LicA1 affecting 
conserved residues of the α-peptides, which included changes in residues involved in the 
formation of Lan and MeLan rings and other amino acids. All these mutations will be 
discussed in the following sections.  
 
4.5.1 Bliα mutagenesis of conserved residues 
 
The α-peptides of two-component lantibiotic have a high homology with mersacidin. 
Thus, the alignment of several of these lantibiotics such as staphylococcin C55 (Navaratna 
et al., 1999), plantaricin W (Holo et al., 2001), haloduracin (McClerren et al., 2006) and 
lacticin 3147 (Ryan et al., 1996; Martin et al., 2004) allowed to identify a set of conserved 
amino acids (Figure 18). The residues TX(T/S)XECX(XX)C appear to form the rings that 
comprise the main site for the interaction with lipid II, especially the C-ring (Cotter et al., 
2006). 
 
Only two of the conserved amino acids of mersacidin-like peptides are not involved in 
the formation of Lan and/or MeLan bridges: the Gly (G18 in Bliα) and the Glu (E26 in Bliα). 
In the present study, a non-active mutant was identified where the E26 residue was 
replaced by an Asp (Figure 20). This was in agreement with what has been already 
reported, in which the alteration E26A resulted in a fully produced peptide, however its 
antibacterial activity was completely abolished (Caetano et al., 2011a). Moreover, when 
the corresponding residues in mersacidin (Szekat et al., 2003), Halα (Cooper et al., 2008) 
Figure 18: Alignment of α-peptides of some two-component-peptide lantibiotics and mersacidin. Black arrows 
indicate the amino acids conserved in mersacidin-like peptides. Blue arrows show the residues conserved among α-
peptides, but not mersacidin. 
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and Lntα (Cotter et al., 2006) were substituted by Ala, the peptides produced were 
inactive. These results were due to the fact that this Glu is essential for the binding of the 
peptides to its target lipid II (Szekat et al., 2003). 
The LC-ESI-MS analysis of extracts of the mutant E26D of Bliα showed that the 
peptide is being produced, however it is also completely inactive. This result showed that 
the substitution of Glu is not possible in these peptides, even when the negative charge is 
maintained (as is the case of Asp). A modification in the G18 residue to Arg was also 
identified in a clone that completely lacks bioactivity (Figure 20). A similar mutation in the 
α-peptide of lacticin 3147 (G16R) also resulted in the abolishment of activity (Field et al., 
2013). Thus, this residue is also not tolerant to amino acid changes, being therefore 
essential to the bioactivity of the lantibiotics. 
C21, T22, C27 and C31 are the conserved residues involved in the formation of the B-, 
C- and D-rings of Bliα. In our library, the following mutations were identified in these four 
residues: C21S, C27Y, C27F, T22I, C31S and C31R and none of these clones were able to 
inhibit growth of M. luteus (Figure 19). The exception was T22R substitution, which 
showed an inhibition zone with half of the size when compared with the control. This 
result was not expected because the modification of T22 by Ala, previously described by 
Caetano et. al (2011a), resulted in a peptide without antibacterial activity. Hence, it was 
concluded that formation of the Bliα C-ring was essential to bioactivity. The presence of 
an Arg residue instead of T22 prevents the formation of this ring in the mutated peptide. 
Nevertheless, the clone showed some bioactivity. Therefore, further studies will be 
required to understand the reason behind such phenotype. 
 
 
 
Figure 19: Changes in Ser/Thr and Cys residues in Bliα and their respective bioactivities. In red are the mutations 
which cause a total abolishment of the activity. In orange are represented mutations that greatly affect the 
bioactivity and so the mutants show a very low bioactivity. In green are the mutations which cause a reduction to 
half of the bioactivity when compared to the control. 
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There are two conserved amino acids among α-peptides, but not in mersacidin 
(Figure 18). These correspond to the G15 and N16 residues in Bliα. In this work, the 
mutation N16K was identified in a clone with no detectable activity (Figure 20). This lack 
of activity is not due to the absence of BliαN16K production, since the mutated peptide 
(M= 3264 Da) was identified by LC-ESI-MS analysis. A similar result was found in the N14 
residue from Ltnα when it is substituted by Ala, highlighting the importance of this 
residue among α-peptides of the two-component lantibiotics (Cotter et al., 2006).  
 
4.5.2 Mutations in other Cys, Ser and Thr residues of Bliα 
 
In this study, 6 from a total of 10 mutants with changes in amino acids involved in the 
formation of Bliα Lan and MeLan tioether rings, showed no activity towards M. luteus. 
This was not surprising since previous studies on other class II lantibiotics demonstrated 
that changes in these residues resulted in a decrease or a total loss of bioactivity 
(Ottenwälder et al., 1995; Bierbaum et al., 1996). The proposed residues involved in the 
two Lan and the two MeLan rings in Bliα are: S5 and C7 form the A-ring, S11 and C21 to 
the B-ring, T22 and C27 for C-ring and T24 and C31 for D-ring (Begley et al., 2009; Caetano 
et al., 2011a). The mutations involved in the B-, C- and D-rings were discussed in the 
previous sections because they are part of the conserved motifs of the mersacidin-like 
lantibiotics. Regarding the A-ring, the following mutations were detected: S5R, S5N and 
C7Y (Figure 19). The outcome of these alterations, in terms of bioactivity, was quite 
variable: S5R was inactive and S5N showed a reduction to half of bioactivity when 
compared to the control. The clone with the C7Y modification presented a very low 
activity against M. luteus. When S5 and C7 residues were independently substituted by 
Ala, the bioactivity was reduced to half (Caetano et al., 2011a) . Thus, our results also 
confirm that the A-ring is not as important as the other rings for the antibacterial activity 
of Bliα. Nevertheless, mutations altering the charge of the residues (such as S5R) are not 
tolerated. 
 Bliα peptide possesses 7 Ser and Thr residues that are posttranslationally dehydrated 
and one Ser (S30) that escapes this modification (Begley et al., 2009). In the present 
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study, two different mutations in this Ser residue were identified: S30G and S30C (Figure 
19). The S30G mutant showed a reduction to half of the antimicrobial activity in 
comparison to the control. This result is in agreement with the documented S30A 
modification, in which bioactivity was decreased but not abolished (Caetano et al., 
2011a). However, the substitution of S30 by a Cys resulted in a clone without antibacterial 
activity. An explanation for this can be the fact that one Cys in that position may interfere 
with the correct formation of the D-ring, which is a very important ring for bioactivity. For 
instance, when some residues of Nisin and Pep5 were modified to Cys, a decrease on the 
activity was also observed (Cotter et al. 2005b). 
The residues Thr3 and Thr6 are both dehydrated to Dhb in the mature Bliα.  In this 
study, the following mutations were detected in the T3 residue: T3A, T3M and T3R. All of 
these changes resulted in total lack of bioactivity (Figure 19). These results are not in 
accordance with others where the same mutation (T3A) was studied, but where only a 
reduction to half of the bioactivity was observed (Caetano et al., 2011a). Therefore, this 
result should be further confirmed. In the literature, it has been referred that the 
consequence of mutating Dha and Dhb residues probably depends on the location of the 
residue within the peptide (Cotter et al. 2005b). When Dhb residues in Pep5 were replace 
by Ala (T16A and T20A), a significant loss of activity was also observed. However, when 
the Dhb in nisin Z was changed to Ala and Val (T2A and T2V), the clones displayed either 
wild-type or close to wild-type levels of activity (Cotter et al., 2005b). 
As previously described, after proteolysis of the leader sequence, a spontaneous 
deamination of the Dhb1 to a 2-oxobutyryl (Obu1) occurs in Bliα. Herein, two mutations 
were identified in this residue: T1A and T1Q. Both resulted in a decrease to half of the  
bioactivity (Figure 19), demonstrating that this residue is not very important to Bliα 
peptide activity, as previously suggested by Caetano et al. (2011a). 
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4.5.3 Mutations in other residues of Bliα  
 
Some clones possessing mutations not involving conserved or other Ser and Thr 
residues were identified in this study. One such mutation is Y19C, which was previously 
associated with very low activity (Figure 20). Tyr is an aromatic amino acid and this type 
of residues have membrane-seeking properties (Cotter et al., 2006). Additionally, and 
more importantly, the insertion of an extra Cys in the core peptide of Bliα will most 
probably disturb the correct formation of Lan/MeLan rings. Nevertheless, it will be 
interesting to establish if in this situation, 5 rings will be formed instead of the four 
normally occurring. Other mutations in residues located inside of the B- and C-ring were 
detected, including P13A, P13L, N16K, G18R, L20P, L20Q, V23E and P29S. The analysis of 
the antibacterial activity of these mutants demonstrated, once more, that introduction of 
charged amino acids instead of neutral residues should be avoided (N16K, G18R and 
V23E) (Figure 20). Pro is an amino acid important at the structural level. However, the 
significance of these residues seems difficult to predict. For instance, the substitution of 
P13 by a Leu results in a peptide that can be identified by LC-ESI-MS analysis, but is 
inactive. Yet, altering the same residue to an Ala results in a peptide that is still active. 
This same phenotype was obtained in a clone possessing a Ser instead of P29 amino acid. 
Also, an inactive peptide was produced when a Pro was inserted in the position 20, 
instead of a Leu. Still, the L20Q mutation resulted in a active peptide (half bioactivity). 
Thus, our results suggest that the chemical nature of the substitution is critical for the 
bioactivity. Other three mutations were found in the region between the A- and the B-
ring, which were A8V, A8T and I9N. Regarding the two mutations in the residue A8, only a 
reduction of the bioactivity was detected, showing that this position can be tolerant to 
changes in amino acids. The clone possessing the I9N alteration produced a small 
inhibition area. However, this outcome is most probably associated with the introduction 
of a positively charged amino acid (Arg) than with the functionality of the Ile residue 
(Figure 20). 
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4.6 Mutations detected in Bliβ 
 
Like in Bliα, several types of mutations were identified in the core peptide of LicA2 
affecting conserved residues of the β-peptide, which included changes in residues 
involved in the formation of Lan and MeLan bridges and other amino acids. All these 
mutations will be discussed in the following sections. 
 
4.6.1 Bliβ mutagenesis of conserved residues 
 
For β-peptides, there is not a representative like mersacidin for α-peptides. However, 
the alignment of several β-peptides of two-component lantibiotics reveals the presence 
of conserved residues, especially at their C-terminal (Figure 21). These constitute the core 
motif SXXXCPTT(K/A)C(T/S)XXC (Cotter et al. 2006; Cotter et al. 2005b). It has been 
suggested that this conserved motif might have an important role in the mode of action 
of lacticin 3147, specifically for the interaction of Ltnβ with Ltnα (Cotter et al., 2006). 
 
 
 
 
 
 
 
Figure 20: Bliα mutations found not in Ser/Thr and Cys residues and their respective bioactivities. In red are the 
mutations which cause a total abolishment of the bioactivity. In orange are represented mutations that greatly affect 
the bioactivity and so the mutants show a very low bioactivity. In green are the mutations which cause a reduction to 
half of the bioactivity when compared to the control.  
Figure 21: Alignment of β-peptides of some two-component lantibiotics. Black arrows indicate the amino 
acids conserved in all the peptides. Blue arrows show other highly conserved amino acids. 
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Considering these conserved residues, mutations on the C23, T25, C28, T29 and C32 
amino acids of Bliβ were identified in clones without bioactivity (Figure 22). All of these 
amino acids are involved in bridge formation: the C23 forms the B-ring with S19, C28 
forms the C-ring with T25 and C32 forms the D-ring with T29. Thus, these results confirm 
that the formation of these three rings should be completely essential either for 
bioactivity or production of the fully maturated peptide. For instance, it was found that 
the mutated BliβT25A peptide was not produced and therefore no antibacterial activity 
could be associated to it (Caetano et al., 2011a). These same conclusions were inferred 
from studies involving the random mutagenesis of Ltnβ peptide (Cotter et al., 2006). 
The T26 residue of Bliβ is the only amino acid of the conserved motif that is not 
involved in the formation of thioether bridges. Also, it is one of the Thr residues that is 
dehydrated in Bliβ (Begley et al., 2009; Caetano et al., 2011a). In the present study, two 
mutations were found for T26 (Figure 22). While T26A mutation showed a reduction to 
half of the activity when compared with the control. The T26I mutation resulted in a 
greater loss of bioactivity. This result suggests that despite the high degree of 
conservation of this residue among β-peptides, it does not necessarily indicate that it 
absolutely essential.  
 
4.6.2 Mutations in other Ser, Thr and Cys residues of Bliβ 
 
None of the residues involved in the A-ring formation are conserved among the β-
peptides of two-component lantibiotics, suggesting that this Lan bridge is not essential for 
bioactivity. However, in the present study, one of the inactive clones possessed a 
mutation in the Cys of A-ring to a Phe (C11F; Figure 22). Yet, its alteration by an Ala 
Figure 22: Bliβ mutations found in conserved residues of β-peptides and other Ser, Thr and Cys residues with their 
respective bioactivities. In red are the mutations that caused a total abolishment of the bioactivity. In orange are 
represented mutations that greatly affect the bioactivity and so the mutants show a very low bioactivity. In green 
are the mutations that caused a reduction to half of the bioactivity when compared to the control. 
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caused only reduction in bioactivity (Caetano et al., 2011a). Moreover, in its homologous 
Halβ, the A-ring was considered dispensable for bioactivity.  Thus, the absence of the A-
ring together with a presence of an amino acid containing an aromatic ring should be a 
dramatic structural change for the peptide. Thus, it will be interesting to analyze if this 
peptide is produced and this will be done in a due time. 
In Bliβ, there are three residues (S21, T26 and S30) that are not dehydrated by the 
cyclase-dehydratase LicM2. It is common over the lantibiotics that Ser/Thr residues 
escape dehydration. However, it is not clear how synthetases select these residues. 
Nevertheless, some authors consider that these amino acids have a key role in the 
biological activity of the final compound (Rink et al., 2005; Cooper et al., 2008). 
Considering the three non-hydrated, mutations were only detected for Ser30 and T26 
(Figure 22). The S30R mutant retained half of the bioactivity, when compared with the 
control. A similar result was also obtained, for S30A substitution (Caetano et al., 2011a). 
Thus, this residue is important for bioactivity, but not essential. T26 mutations have been 
discussed above. 
Among the other Ser and Thr residues that are dehydrated, mutations were 
identified only for T1, T6, S8, T13 and T17 (Figure 22). Most of these involved 
substitutions with charged amino acids or Pro (T1R, S8P, T13R and T17P) in which the 
antibacterial activity was abolished. Yet, other mutation in T17 was detected (T17M) 
where the bioactivity was nonexistent, suggesting that this residue (T17) is not very 
tolerant to changes. Regarding T13, was detected other modification (T13I), where the 
bioactivity was only reduced. The same result was obtained for T13A mutation (Caetano 
et al., 2011a). Thus, the phenotype of T13R should be more related with the presence of a 
positive charge than with the functionality of the original amino acid. The last mutation of 
a dehydrated amino acid was T6A. The result obtained in this study for T6A was 
absolutely in agreement with the alanine scan performed previously by Caetano et al. 
(2011a). 
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 4.6.3 Mutations in other residues of Bliβ   
 
The mutations identified in this study involving other residues of the Bliβ peptide 
were limited to the amino acids P3, A4, W9, I12, G15, V18, A20 and K27 (Figure 23). Once 
more, the introduction of negatively charged amino acids implicated always the absence 
of bioactivity (G15D, V18D, A20D and K27E). Thus, like in Bliα, when charged amino acids 
are introduced, a big impact on the bioactivity was observed. However, the K27M 
mutation had not a so detrimental effect on activity as K27E. Substitutions with Cys were 
also associated with very low or loss of activity (W9C and G15C). This is also 
understandable because lantibiotics known so far do not have free Cys residues. 
Therefore, insertion of an additional Cys in the core peptide will most probably result in 
formation of a novel ring or will disturb the normal ring-topology.  
Other mutations detected that resulted in a reduction of bioactivity were P3H and 
A4P. The latter involves the presence of an additional Pro in Bliβ. Thus, as observed for 
Bliα, the replacement of a given residue by a Pro or the introduction of a Pro, have a 
negative impact in the antimicrobial activity. The first (P3H) will imply the loss of the first 
Pro in Bliβ and the presence of a positive charge (His). I12T is another mutation found 
that resulted in very low activity, maybe because the insertion of an additional Thr 
residue can alter the dehydration pattern of the entire peptide. This should be further 
investigated through the analysis of the MS/MS pattern of the produced peptide.  
 
 
Figure 23: Bliβ mutations found in other residues and their respective bioactivities. In red are the mutations that 
caused a total abolishment of the bioactivity. In orange are represented mutations that greatly affect the bioactivity 
and so the mutants show a very low bioactivity. In green are the mutations which cause a reduction to half of the 
bioactivity when compared to the control. 
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5. Conclusions and Future Perspectives 
 
Studies involving the bioengineering of lantibiotics to produce new variants of these 
peptides have been increasing in the last years. One of the main goals has been the 
identification of peptides with improved activity. However, this has been proven difficult. 
Therefore, bioengineering studies are also often used to provide information on the 
structure-function relationship of lantibiotics. 
Among the two-component lantibiotics, random mutagenesis libraries was obtained 
only for lacticin 3147. The approach used in the study described by Field et al. (2007) 
implied the generation of only one library, where the mutagenesis of the lacticin 3147 
peptides was performed simultaneously. Though, the antibacterial activity of two-
component lantibiotics depends on the synergy between the two peptides. Thus, in this 
study, the impact of mutations in the bioactivity of lichenicidin peptides (Bliα and Bliβ) 
was investigated by mutagenesis of each peptide separately. Consequently, the 
complementary peptide was always provided in its wild-type form in the bioactivity 
assays. Therefore, two random mutagenesis libraries for lichenicidin were produced and 
the antibacterial activity of around 4000 clones from each library was analyzed.  
Herein, it was not possible to identify mutants with improved activity against 
M. luteus. In fact, the identification of lantibiotics with this characteristic has been 
difficult. One successful example was nisin, a class 1 lantibiotic, where a mutant 
generated by random mutagenesis exhibited enhanced efficacy against both Gram-
positive and Gram-negative bacteria (Field et al., 2012). Yet, one of the objectives was 
also to recognize mutations in lichenicidin peptides resulting in reduced or null activity. 
This would retrieve more information on the structure-activity of lichenicidin. Moreover, 
interesting mutants can also be used in studies of their mode of action. Indeed, it was 
possible to identify several mutations related with the reduction of bioactivity. The 
majority of them were found in the core peptide of LicA1 and LicA2, suggesting that single 
mutations in the leader sequence do not have much impact in biosynthesis. An exception 
to this was an inactive clone identified in the Bliβ library possessing the A22E mutation in 
the leader sequence. Other interesting mutations detected in this study were in the 
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double-Gly motif. The G43E (Bliα) and G36V (Bliβ) variants still retained some bioactivity. 
This was not expected, since they would prevent the proteolysis of the leader sequence. 
Therefore, the clones with these three mutations should be further studied in detail in 
order to clarify their real impact at the biosynthetic level.  
Considering the core peptide, several mutations on residues involved in conserved 
domains or in the formation of rings (especially on the C-terminal) were identified. 
Substitutions involving charged amino acids or prolines were also detected. Therefore, 
our study showed that the bioengineering strategies for these peptides should focus on 
their N-terminal and avoid the use of charged amino acids and prolines. Previously, the 
importance of the Glu26 of Bliα, and its counterparts in class II lantibiotics, was already 
established. However, in our study, it was shown that its most similar amino acid (Asp) is 
not able to play the same role as Glu26 in the mode of action of lichenicidin. Therefore, it 
could be interesting to compare this derivative of Bliα with the wild-type in studies 
involving the interaction with lipid II. Regarding the Bliβ variants herein studied, it will be 
necessary to perform LC-MS analysis studies in order to understand if some of the 
inactive variants herein identified are produced.  
In the future, the nucleotide sequence of more mutants with reduced activity should 
be performed and always supplemented with LC-ESI-MS and LC-ESI-MS/MS analysis. 
Moreover, it will also be interesting the study of mutations occurring in clones that 
showed no altered activity. 
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Appendix 1 – PCR using Promega Taq DNA polymerase and 
Electrophoresis gel 
 
PCR using Promega Taq DNA polymerase 
 
For all the reactions in order to minimize pipetting errors, a PCR master mix was 
performed (PCR master mix content – water, buffer, primers, dNTPs and Promega Taq NA 
polymerase). All solutions were gently vortex and briefly centrifuged (Table 8). 
Table 8: PCR reaction using Promega Taq DNA polymerase 
 
*To perform colony-PCR, instead of the DNA solution as template, one isolated colony is picked to the mixture. The 
required final volume is performed with distilled water. 
 
The mixture was then divided into PCR tubes and one single colony or the regular 
volume is added into the solution. The reactions were then placed in the thermocycler 
(BIO-RAD) and the following thermal cycling conditions were used (Table 9) 
Table 9: Thermal cycling conditions to perform the PCR with Taq DNA polymerase from Promega. 
 
 
*Annealing temperature based on the average of the primers melting temperatures, which was decreased by 5 
degrees. 
Component of the reaction Volume 
5X Taq DNA Buffer 5µL 
dNTP Mix, 10mM each 0.5 µL 
Forward primer (10mM) 0.75 µL 
Reverse primer (10mM) 0.75 µL 
Taq DNA polymerase (5U/ µL) 0.125 µL 
DNA template * 1 µL 
Destilled water Up to 25 µL 
 Temperature (oC) Time Number of cycles 
Initial denaturation 95 3 min 1 
Denaturation 95 30seg  
Annealing Tm-5* 30 seg 30 
Extension 72 1min/kb  
Final extension 72 10 min 1 
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After the amplification reaction the PCR product was stored at -20 oC until further 
use or immediately run in an electrophoresis gel. 
 
Electrophoresis gel 
 
Analysis of PCR products was generally performed on agarose gel electrophoresis. 
The samples were mixed with 6X loading buffer (6X loading buffer composition: 2.5 
mg/mL of bromophenol blue, 2,5 mg/mL of xylene cyanol FF and 30 % (v/v) glycerol; 
stored at 4 oC.) in a proportion of 1:6 (v/v) and loaded in a 1 % agarose gel. The gel was 
prepared with 1X of TAE buffer (Bio-Rad) and EtBr (AppliChem) to a final concentration of 
0.5 μg/mL added before placing the melted agarose in the running tray. In all gels 0.5 μg 
of DNA Ladder Mix (Fermentas) marker was included. Electrophoresis was generally 
performed at 120 V for the desired time and the DNA was analyzed under UV light and 
the image acquired in the ATTO image acquisition system. 
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Appendix 2 - Purification of PCR products, restriction 
digestions and agarose gels 
 
Purification of PCR products and DNA digestions were performed using the 
NZYGelpure (NZYtech) kit, according to the manufacturer’s instructions. 
 
(1) Purification of PCR proucts and restiction digestions  
The volume of the reaction mixture was transferred to a 1.5 mL microcentrifuge 
tube and five volumes of Binding Buffer were added and mixed well. The mixture was 
applied to an NZYTech spin column, incubated at room temperature for 2 min and 
centrifuged for 1 min at top speed. The flow-through was discarded and 600 μL of Wash 
Buffer were added to the spin column. After 2 min of room temperature incubation, the 
column was centrifuge for 1 min and the flow-through was discarded. An additional 1 min 
centrifugation was performed to remove residual ethanol. The NZYTech spin column was 
then placed into a clean 1.5 mL microcentrifuge tube and 30 to 50 μL of sterile distilled 
water were added to the center of the column. The DNA-containing column was 
incubated at room temperature for 2 min and then centrifuged for 1 min to elute the 
DNA. The sample was stored at -20 oC until further use. 
 
(2) Purification of DNA from agarose gel 
Regarding the NZYGelpure kit manufacture’s instructions. Carefully, the desired 
DNA fragment was excised from the agarose gel with a clean scalpel and placed in a 1.5 
mL microcentrifuge tube. The gel slice was weighted and 300 µL of Binding Buffer for 
each 100 mg of gel weight was added. The tube was incubated at 60 oC for 10 minutes 
and occasionally stirred until agarose is completely dissolved. 1 gel volume of isopropanol 
was added and mixed by pipetting several times. The sample was then applied to a 
NZYTech spin column that is placed intro a Collection tube (2 ml) and centrifuged for 1 
minute and the flow-through was discarded. And the column was placed back to the 
collection tube. The column was washed with 500 µL of Wash Buffer and centrifuged for 
one minute. The flow-through was discharged and one other washed step was performed 
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adding 600 µL of Wash Buffer and again the column was centrifuged for one minute and 
the flow-through was discarded and the column was centrifuged for an additional minute 
to ensure the complete removal of residual ethanol. The NZYTech spin column, was 
placed in a clean 1.5 mL microcentrifuge tube and the DNA was eluted in 30 to 50 μL of 
sterile Elution Buffer. The elution is performed after 2 min of incubation at room 
temperature by centrifugation for 2 min at top speed. The sample was stored at -20 oC 
until further use. 
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Appendix 3 - DNA concentration – Qubit® (Invitrogen) 
  
In order to quantify the DNA amount of the sample, a master mix was performed 
in a 1.5 mL tube and for each sample 199 µL of Qubit® dsDNA HS Assay buffer was added 
and 1 µL of DNA standard was also added to the final master mix. The master mix was 
vortex and suffer a fast spin step. In the next step, 199 µL of the master mix was 
introduced into a small tube for the Qubit® and 1 µL of DNA from the sample was also 
added. The tubes were vortex for 2-3 seconds, incubated at room temperature for 2 min 
and the concentration was read in the Qubit® Flurometer. 
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Appendix 4 - Plasmid and Fosmid extraction 
 
(1) Plasmid extraction with EzWayTMPlasmid DNA Kit ( Komabiotech) 
 
The routine extraction of plasmid DNA from E. coli was performed 
EzWayTMPlasmid DNA Kit (Komabiotech) according to manufacturer’s instructions. A 
bacteria culture with the desired plasmid was growth overnight in the LB medium 
supplemented with the respective selective markers, at 37 oC and 180 rpm. 3 ml of well-
grown bacteria culture was transferred to a microcentrifuge tube and the bacteria was 
descended by a centrifugation step for 1-2 min. The supernatant was discarded and the 
pellet was suspended by pipetting in 250 µl of Resuspension Buffer. 250 µl of Lysis Buffer 
was added and the tube was gently inverted by 5 times (without vortexing) to lyse the 
cells and was incubated at room temperature for 2 min. Neutralization was performed by 
adding 350 µl of Neutralization Buffer and by immediately mixing by inverting the tube 5 
times. The lysate was centrifuged for 10 min at maximum speed and the supernatant was 
transferred to a DNA-prep Column. After centrifugation for 1 min the flow-through was 
discarded, the column was placed in the same collection tube and 400 µl of Wash-Buffer 
A was added into the column. The column was centrifuged for 1 min, the flow-through 
was discarded and the column was washed again with 750 µl of Wash-Buffer B (with 
ethanol added). The column was centrifuged again for 1 min, the flow-through was 
discarded and the column was additional centrifuged for 3 min in order to remove 
residual ethanol. Finally the column was transferred to a sterile 1.5 microcentrifuge tube 
and the elution of the plasmid DNA was performed by adding 40 µl of Elution Buffer into 
the center of the membrane column, incubation for 1 min at room temperature and 
centrifugation at maximum speed for 1 min. 
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(2) Fosmid extraction with traditional alkaline lysis   
To extract fosmid DNA, columns cannot be used because of DNA large size. 
However, the protocol can be performed using the reagents from the QIAprep 
Spin MiniPrep Kit (QIAGEN).  
In order to extract the fosmid, the bacterial strain was grown overnight in 
LB medium with the appropriate antibiotic and 10 mL of the bacterial culture was 
centrifuged for 1 min at top speed in a to-table centrifuge. The supernatant was 
discarded and the cell pellet was resuspended in 250 μL of buffer P1 at 4 oC. The 
cell lysis was performed by the addition of 250 μL of lysis buffer (P2) and mixing, 
followed by the addition of 350 μL of P3 buffer. The mixture was centrifuged for 5 
min at maximum speed and the supernatant was transferred to a clean 1.5 mL 
microcentrifuge tube. 1 volume of phenol:CIA was added and mixed well. Another 
centrifugation was performed in the same conditions as mentioned before. The 
aqueous upper phase was collected to a new microcentrifuge tube. 1/10 volume 
of 0.3 M of NaAc (pH 5.2) and 0.6 volume of isopropanol were then added to the 
recovered supernatant and the mix was incubated at room temperature for 15 
min followed by a centrifugation at 4 oC, top speed for 15 min. The white pellet 
formed was washed with 1 mL of 70 % (v/v) ethanol and centrifuged 5 min at 
maximum speed. After removal of ethanol, the pellet was air-dried to remove 
residual ethanol. Finally the pellet was resuspended in 30 μL of sterile distilled 
water.
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Appendix 5 - Clones and respective mutations and 
bioactivity of Bliα 
 
Table 10: Clones from LicA1 and respective mutations and bioactivity (NA- null activity, RA- reduced activity, VLA – very 
low activity). 
Clone 
Leader 
peptide 
Core 
peptide 
Both (core and 
leader) 
GG 
Frame 
Shift 
STOP 
codon 
Bioactivity 
NA_1.2_A1 - C71Y - - - - NA 
NA_1.8_A1 - T47M - - - - NA 
NA_1.13_A1 - T66I - - - - NA 
NA_1.15_A1 - C75S - - - - NA 
NA_1.16_A1 - L64P - - - - NA 
NA_1.19_A1 - N60K - - - - NA 
NA_1.24_A1 - C71F - - - - NA 
NA_1.27_A1 - T47A - - - - NA 
RA_1.23_A1 - P57L - - - - NA 
NA_1.32_A1 - T47A - - - - NA 
NA_1.14_A1 - S74C - - - - NA 
NA_1.34_A1 - C75R - - - - NA 
NA_1.36_A1 - T47R - - - - NA 
NA_1.37_A1 - S49R - - - - NA 
NA_1.38_A1 - C65S - - - - NA 
NA_1.46_A1 - E70D - - - - NA 
RA_1.14_A1 - G62R - - - - NA 
RA_1.19_A1 - V67E - - - - NA 
RA_1.15_A1 - L64Q - - - - RA 
RA_1.21_A1 - P57A - - - - RA 
RA_1.26_A1 - T45K - - - - RA 
RA_1.27_A1 - T45A - - - - RA 
RA_1.28_A1 - T66R - - - - RA 
RA_1.31_A1 - P73S - - - - RA 
VLA_1.8_A1 - A52V - - - - RA 
VLA_1.12_A1 - A52V - - - - RA 
VLA_1.19_A1 - S74G - - - - RA 
VLA_1.22_A1 - A52T - - - - RA 
RA_1.2_A1 - A52V - - - - RA 
RA_1.9_A1 - P73S - - - - RA 
VLA_1.37_A1 - S49N - - - - RA 
VLA_1.42_A1 - A52T - - - - RA 
VLA_1.15_A1 - I53N - - - - VLA 
RA_1.11_A1 - C51Y - - - - VLA 
NA_1.7_A1   - Y63C - - - - VLA 
NA_1.33_A1 - Y63C - - - - VLA 
NA_1.42_A1 - Y63C - - - - VLA 
RA_1.10_A1 - Y63C - - - - VLA 
NA_1.28_A1 - Y63C - - - - VLA 
NA_1.4_A1 - - - G44C - - NA 
RA_1.17_A1 - - - G43E - - RA 
VLA_1.38_A1 T19I;P25Q - - - - - RA 
RA_1.3_A1 - I46V; V67A - - - - RA 
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NA_1.11_A1 - T47M;L64Q - - - - NA 
VLA_1.28_A1 - T47M;L64Q - - - - NA 
RA_1.13_A1 - - L33P;I53F - - - RA 
RA_1.25_A1 - - S40R;P73L - - - RA 
RA_1.16_A1 - - Q34H;L58V - - - RA 
NA_1.44_A1 - - G44C;L64M - - - NA 
VLA_1.39_A1 - - A26V;P73R - - - NA 
NA_1.20_A1 - - K6R; T47A - - - NA 
NA_1.5_A1 - - Y17C;I68T - - - NA 
VLA_1.21_A1  - - N28S;Y63N - - - VLA 
RA_1.30_A1 - - K31R;S49G - - - VLA 
NA_1.30_A1 - - - - Delection - NA 
NA_1.6_A1 - - - - Delection - NA 
NA_1.10_A1 - - - - Delection - NA 
NA_1.23_A1 - - - - Delection - NA 
NA_1.21_A1 - - - - Insertion - NA 
NA_1.9_A1 - - - - Delection - NA 
NA_1.39_A1 - - - - Delection - NA 
NA_1.40_A1 - - - - Delection - NA 
NA_1.21_A1 - - - - Insertion - NA 
NA_1.17_A1 - - - - - G43STOP NA 
NA_1.31_A1 - - - - - L54STOP NA 
NA_1.35_A1 S40R - - - - G59STOP NA 
NA_1.43_A1 - L48P - - - Y17STOP NA 
NA_1.1_A1 - (I53V) - - - E32STOP NA 
RA_1.3_A1 - I46V; V67A - - - - NA 
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Appendix 6 - Clones and respective mutations and 
bioactivity of Bliβ 
 
Table 11: Clones from LicA2 and respective mutations and bioactivity (NA- null activity, RA- reduced activity, VLA – very 
low activity). 
Sample 
Leader 
peptide 
Core 
peptide 
Hexapeptide 
Both (core 
and 
leader) 
GG 
Frame 
Shift 
STOP 
codon 
Bioactivity 
NA_1.6_A2 - T55R - - - - - NA 
NA_1.11_A2 - T43R - - - - - NA 
NA_1.16_A2 - T67I - - - - - NA 
NA_1.19_A2 - G57D - - - - - NA 
NA_1.21_A2 - T67A - - - - - NA 
NA_1.24_A2 - C70S - - - - - NA 
NA_1.26_A2 - C53F - - - - - NA 
NA_1.28_A2 - S50P - - - - - NA 
NA_1.29_A2 - T71A - - - - - NA 
RA_1.20_A2 - T59M - - - - - NA 
VLA_1.9_A2 - C65R - - - - - NA 
VLA_1.8_A2 - C65R - - - - - NA 
VLA_1.23_A2 - T59P - - - - - NA 
VLA_1.25_A2 - T67R - - - - - NA 
VLA_1.28_A2 - W51C - - - - - NA 
NA_1.2_A2 - C65S - - - - - NA 
NA_1.3_A2 - C74R - - - - - NA 
NA_1.5_A2 - T71I - - - - - NA 
NA_1.24_A2 - C70S - - - - - NA 
NA_1.27_A2 - A62D - - - - - NA 
NA_1.7_A2 - C65S - - - - - NA 
NA_1.31_A2 - T71R - - - - - NA 
NA_1.36_A2 - T67I - - - - - NA 
NA_1.41_A2 - T67A - - - - - NA 
NA_1.42_A2 - C65S - - - - - NA 
RA_1.6_A2 - V60D - - - - - NA 
VLA_1.7_A2 - K69E - - - - - NA 
VLA_1.27_A2 - K69E - - - - - NA 
NA_1.20_A2 - A46P - - - - - VLA 
VLA_1.4_A2 - I54T - - - - - VLA 
VLA_1.12_A2 - G57C - - - - - VLA 
RA_1.17_A2 - T68I - - - - - VLA 
VLA_1.29_A2 - V39G;P45H - - - - - VLA 
RA_1.15_A2 - P45H - - - - - RA 
RA_1.18_A2 - T48A - - - - - RA 
RA_1.19_A2 - K69M - - - - - RA 
RA_1.7_A2 - S72R - - - - - RA 
VLA_1.11_A2 - P45H - - - -  RA 
VLA_1.18_A2 - T55I - - - -  RA 
VLA_1.22_A2 - T68A - - - -  RA 
VLA_1.30_A2 - T68A - - - -  RA 
RA_1.21_A2 - - P41H - - - - RA 
NA_1.15_A2 - - E42K - - - - RA 
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RA_1.27_A2 - - - - G36V - - RA 
VLA_1.26_A2 A22E - - - - - - NA 
RA_1.23_A2 P21T - - - - - - RA 
RA_1.29_A2 P21S - - - - - - RA 
RA_1.30_A2 H20R - - - - - - RA 
NA_1.23_A2 - - - L30S;G57D - - - NA 
VLA_1.19_A2 - - - M6T; T43A - - - NA 
RA_1.26_A2 - - - P21Q;S61F - - - NA 
VLA_1.13_A2 - - - A10V;C65S - - - NA 
RA_1.2_A2 - - - N19K;L64I - - - RA 
RA_1.12_A2 - - - L33F;A56V - - - RA 
RA_1.10_A2 - - - P21Q;M24I - - - VLA 
RA_1.11_A2 N19D - - - G35E - - RA 
VLA_1.17_A2 R12H - - - - G36R - VLA 
VLA_1.10_A2 - L64S - - N40I - - VLA 
NA_1.32_A2 - - - - - Delection - NA 
NA_1.35_A2 - - - - - Delection - NA 
NA_1.37_A2 - - - - - Delectio - NA 
NA_1.39_A2 - - - - - Delection  NA 
NA_1.30_A2 - - - - - - G36STOP NA 
NA_1.9_A2 - - - - - - R73STOP NA 
NA_1.4_A2 - - - - - - R73STOP NA 
NA_1.18_A2 - - - - - - L33STOP NA 
NA_1.33_A2 V34L - - - - - K31STOP NA 
NA_1.34_A2 V34A - - - - - L33STOP NA 
NA_1.38_A2 H20L - - - - - G17STOP NA 
NA_1.43_A2 - - - - - - R73STOP NA 
NA_1.17_A2 A18P - - - - - G35STOP NA 
NA_1.25_A2 - C53F - - - - R73STOP NA 
VLA_1.15_A2 H20Y;E27G - N37D - - - - VLA 
